These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 20929391)

  • 41. Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir.
    Llibre JM; Domingo P; Palacios R; Santos J; Pérez-Elías MJ; Sánchez-de la Rosa R; Miralles C; Antela A; Moreno S;
    AIDS; 2006 Jun; 20(10):1407-14. PubMed ID: 16791015
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Triple-class HIV antiretroviral therapy failure in an Australian primary care setting.
    Bloch M; Farris M; Tilden D; Gowers A; Cunningham N
    Sex Health; 2010 Mar; 7(1):17-24. PubMed ID: 20152091
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment.
    Lapadula G; Cozzi-Lepri A; Marchetti G; Antinori A; Chiodera A; Nicastri E; Parruti G; Galli M; Gori A; Monforte Ad;
    AIDS; 2013 Mar; 27(5):769-79. PubMed ID: 23719349
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
    Khanna N; Opravil M; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Weber R; Hirschel B; Battegay M; Kaufmann GR;
    Clin Infect Dis; 2008 Oct; 47(8):1093-101. PubMed ID: 18783328
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevalence and risk factors for clinically significant drug interactions with antiretroviral therapy.
    Miller CD; El-Kholi R; Faragon JJ; Lodise TP
    Pharmacotherapy; 2007 Oct; 27(10):1379-86. PubMed ID: 17896893
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Short communication: three years follow-up of first-line antiretroviral therapy in cambodia: negative impact of prior antiretroviral treatment.
    Ségéral O; Limsreng S; Nouhin J; Hak C; Ngin S; De Lavaissière M; Goujard C; Taburet AM; Nerrienet E; Delfraissy JF; Ouk V; Dulioust A
    AIDS Res Hum Retroviruses; 2011 Jun; 27(6):597-603. PubMed ID: 21083413
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lipid profile changes in Thai HIV and tuberculosis co-infected patients receiving non-nucleoside reverse transcriptase inhibitors-based antiretroviral therapy.
    Mankhatitham W; Luaengniyomkul A; Manosuthi W
    J Med Assoc Thai; 2012 Feb; 95(2):163-9. PubMed ID: 22435244
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Factors associated with mortality among persistently viraemic triple-antiretroviral-class-experienced patients receiving antiretroviral therapy in the HIV Outpatient Study (HOPS).
    Palella FJ; Armon C; Buchacz K; Chmiel JS; Novak RM; D'Aquila RT; Brooks JT;
    J Antimicrob Chemother; 2014 Oct; 69(10):2826-34. PubMed ID: 24942257
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study.
    Glass TR; Ungsedhapand C; Wolbers M; Weber R; Vernazza PL; Rickenbach M; Furrer H; Bernasconi E; Cavassini M; Hirschel B; Battegay M; Bucher HC;
    HIV Med; 2006 Sep; 7(6):404-10. PubMed ID: 16903986
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prevalence and clinical characteristics of HIV type 1-infected patients receiving dialysis in Spain: results of a Spanish survey in 2006: GESIDA 48/05 study.
    Trullàs JC; Barril G; Cofan F; Moreno A; Cases A; Fernandez-Lucas M; Martinez-Ara J; Ceballos M; Garcia-de-Diego J; Muñiz ML; Molina J; Martínez-Castelao A; González-Garcia J; Miró JM;
    AIDS Res Hum Retroviruses; 2008 Oct; 24(10):1229-35. PubMed ID: 18834322
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors.
    Guaraldi G; Squillace N; Stentarelli C; Orlando G; D'Amico R; Ligabue G; Fiocchi F; Zona S; Loria P; Esposito R; Palella F
    Clin Infect Dis; 2008 Jul; 47(2):250-7. PubMed ID: 18532884
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Increased risk of non-AIDS-related events in HIV subjects with persistent low CD4 counts despite cART in the CoRIS cohort.
    Pacheco YM; Jarrin I; Rosado I; Campins AA; Berenguer J; Iribarren JA; Rivero M; Muñoz-Medina L; Bernal-Morell E; Gutiérrez F; Leal M;
    Antiviral Res; 2015 May; 117():69-74. PubMed ID: 25766861
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Aging and HIV infection: a comparison between older HIV-infected persons and the general population.
    Onen NF; Overton ET; Seyfried W; Stumm ER; Snell M; Mondy K; Tebas P
    HIV Clin Trials; 2010; 11(2):100-9. PubMed ID: 20542846
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Risk factors for cardiovascular disease in children infected with human immunodeficiency virus-1.
    Miller TL; Orav EJ; Lipshultz SE; Arheart KL; Duggan C; Weinberg GA; Bechard L; Furuta L; Nicchitta J; Gorbach SL; Shevitz A
    J Pediatr; 2008 Oct; 153(4):491-7. PubMed ID: 18538789
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rate of cardiovascular, renal and bone disease and their major risks factors in HIV-infected individuals on antiretroviral therapy in Spain.
    Knobel H; Domingo P; Suarez-Lozano I; Gutierrez F; Estrada V; Palacios R; Antela A; Blanco JR; Fulladosa X; Refollo E;
    Enferm Infecc Microbiol Clin (Engl Ed); 2019; 37(6):373-379. PubMed ID: 30389268
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HIV infection induces structural and functional changes in high density lipoproteins.
    Siegel MO; Borkowska AG; Dubrovsky L; Roth M; Welti R; Roberts AD; Parenti DM; Simon GL; Sviridov D; Simmens S; Bukrinsky M; Fitzgerald ML
    Atherosclerosis; 2015 Nov; 243(1):19-29. PubMed ID: 26343868
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Dietary intake and cardiovascular risk among people living with HIV/AIDS].
    Deresz LF; Brito C; Schneider CD; Rabito EI; Ikeda MLR; Lago PD
    Cien Saude Colet; 2018 Aug; 23(8):2533-2542. PubMed ID: 30137123
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Risk of coronary artery disease in individuals infected with human immunodeficiency virus.
    Vilela FD; Lorenzo AR; Tura BR; Ferraiuoli GI; Hadlich M; Barros MV; Lima AB; Meirelles V
    Braz J Infect Dis; 2011; 15(6):521-7. PubMed ID: 22218509
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Atherogenic lipid profile and cardiovascular risk factors in HIV-infected patients (Nétar Study).
    Santos J; Palacios R; González M; Ruiz J; Márquez M
    Int J STD AIDS; 2005 Oct; 16(10):677-80. PubMed ID: 16212715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.